Dan Li1,2, YanMei Ji3, JiaLong Guo1, Qiang Guo1,4. 1. Department of Thoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China. 2. Department of Oncology, Huanggang Central Hospital, Huanggang, Hubei, 435300, China. 3. Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China. 4. Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, 430030, China.
Abstract
Aim: The authors investigated the clinical role of MTFR2 in hepatocellular carcinoma (HCC) progression. Results: MTFR2 expression and methylation were abnormal in HCC tissues, and HCC patients with increased MTFR2 expression or methylation had poor or better overall survival, respectively. In addition, increased MTFR2 expression was correlated with age, grade, cancer stage and T stage. MTFR2 was an independent predictor of dismal prognosis in HCC patients. MTFR2 was involved in HCC progression by modulating the cell cycle, homologous recombination, DNA replication, p53 signaling pathway, etc. The ten hub genes were overexpressed in HCC tissues and were linked to cancer stage and dismal prognosis in HCC patients. Conclusion: MTFR2 could be a prospective biomarker of poor prognosis in individuals with HCC.
Aim: The authors investigated the clinical role of MTFR2 in hepatocellular carcinoma (HCC) progression. Results: MTFR2 expression and methylation were abnormal in HCC tissues, and HCC patients with increased MTFR2 expression or methylation had poor or better overall survival, respectively. In addition, increased MTFR2 expression was correlated with age, grade, cancer stage and T stage. MTFR2 was an independent predictor of dismal prognosis in HCC patients. MTFR2 was involved in HCC progression by modulating the cell cycle, homologous recombination, DNA replication, p53 signaling pathway, etc. The ten hub genes were overexpressed in HCC tissues and were linked to cancer stage and dismal prognosis in HCC patients. Conclusion: MTFR2 could be a prospective biomarker of poor prognosis in individuals with HCC.
Authors: Dan Li; Kai Li; Wei Zhang; Kong-Wu Yang; De-An Mu; Guo-Jun Jiang; Rong-Shu Shi; Di Ke Journal: Front Immunol Date: 2022-06-27 Impact factor: 8.786
Authors: Qun-Xian Zhang; Ye Yang; Heng Yang; Qiang Guo; Jia-Long Guo; Hua-Song Liu; Jun Zhang; Dan Li Journal: Transl Cancer Res Date: 2021-10 Impact factor: 1.241
Authors: Maria Rita Braghini; Oriana Lo Re; Ilaria Romito; Maite G Fernandez-Barrena; Barbara Barbaro; Silvia Pomella; Rossella Rota; Manlio Vinciguerra; Matias A Avila; Anna Alisi Journal: J Exp Clin Cancer Res Date: 2022-03-24